Generic Talconex now available

April 3, 2014

Sandoz this week introduced its calcipotriene and betamethasone dipropionate ointment in the United States. It will be the first generic version of Leo Pharma’s Taclonex ointment in the market.

Calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex ointment, was launched in the United States by Sandoz.

Talconex is a vitamin D analogue and corticosteroid combination product used to treat adults with psoriasis vulgaris, which affects approximately 2% of the US population.

“Sandoz is proud to be first-to-market with a generic version of this important therapy,” said Peter Goldschmidt, president of Sandoz US. “This launch further broadens our strong offering of differentiated generic dermatology products.”

Tolmar Inc. owns the Abbreviated New Drug Application for the product and received FDA approval for a generic version. Sandoz will market its calcipotriene and betamethasone dipropionate ointment in partnership with Tolmar.

Talconex produced $96 million in US sales in 2013, according to IMS Health. Sandoz’s generic version will be available in 60-g and 100-g tubes.